Analyst Price Target is $107.42
▲ +437.09% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for H. Lundbeck A/S in the last 3 months. The average price target is $107.42, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 437.09% upside from the last price of $20.00.
Current Consensus is
The current consensus among 5 polled investment analysts is to hold stock in H. Lundbeck A/S. This rating has held steady since July 2021, when it changed from a Buy consensus rating.
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.